Faculty profile

Francesca Cicchetti

ResearcherUniversité Laval

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université Laval directory, so their courses may be missing. Find their university profile.

Francesca Cicchetti

Researcher

Health Sciences

Université Laval

Quebec City, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
23 publications in the last five years, latest in 2026.
Senior (last) author on 14 recent papers, a sign of leading a research group.
Principal investigator on 5 research grants (5 CIHR), most recently in 2019.
Supervised 6 trainees who won CIHR awards, most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Huntington'S Disease Misfolded Proteins Antibody Treatment Blood-Brain-Barrier Lrp-1 Mutant Huntingtin Propagation Neurodegenerative Disorders Parabiosis

Latest papers

WDR44 drives de novo α-synuclein aggregation at the lysosomal membrane and promotes neuronal dysfunction in Parkinson's Disease.
bioRxiv : the preprint server for biology · 2026
Mutant huntingtin in the extracellular matrix: A new perspective on Huntington's disease pathology.
Neurobiology of disease · 2026 · senior author
The impact of tau deletion on Huntington's disease: An in vivo perspective.
Molecular therapy : the journal of the American Society of Gene Therapy · 2026 · senior author

All 72 publications

Latest funding

Rethinking Huntington's disease: using healthy plasma proteins to ameliorate pathology
CIHR · 2023 · Supervisor
$135,000
Preventing pathological protein spread in Huntington's disease: relevance to pathology and treatment.
CIHR · 2019 · Nominated PI
$929,475
Modeling blood-brain barrier dysfunctions using induced pluripotent stem cells: new insights into Huntington's disease pathology
CIHR · 2019 · Supervisor
$90,000

All 12 grants and awards

72 publications.

WDR44 drives de novo α-synuclein aggregation at the lysosomal membrane and promotes neuronal dysfunction in Parkinson's Disease.

Teixeira M, Sheta R, Bérard M, Insinna C, Mahul-Mellier AL, Delmas CVL, Lépinay E, Idi W, Ricard A, Del Cid-Pellitero E, Trabolsi C, Gobeil S, Canron MH, Bézard E, Rajput A, Cicchetti F, Parent M, Fon EA, Ramalingam N, Dettmer U, Calon F, Westlake C, Lashuel HA, Oueslati A

bioRxiv : the preprint server for biology2026

DOI: 10.64898/2026.04.03.716340 PMID: 41993512

Mutant huntingtin in the extracellular matrix: A new perspective on Huntington's disease pathology.

Trabolsi C, Cicchetti F

Neurobiology of disease2026Senior author

DOI: 10.1016/j.nbd.2026.107502 PMID: 42361862

The impact of tau deletion on Huntington's disease: An in vivo perspective.

Lepinay E, Saint-Pierre M, Teixeira M, Snapyan M, Oueslati A, Parent M, Alpaugh M, Cicchetti F

Molecular therapy : the journal of the American Society of Gene Therapy2026Senior author

DOI: 10.1016/j.ymthe.2025.11.033 PMID: 41318997

Erythrocyte-derived extracellular vesicles transcytose across the blood-brain barrier to induce Parkinson's disease-like neurodegeneration.

Denis HL, de Rus Jacquet A, Alpaugh M, Panisset M, Barker RA, Boilard É, Cicchetti F

Fluids and barriers of the CNS2025Senior author

DOI: 10.1186/s12987-025-00646-9 PMID: 40229767

Tau levels in platelets isolated from Huntington's disease patients serve as a biomarker of disease severity.

Alpaugh M, Lantero-Rodriguez J, Benedet AL, Manseau U, Boutin M, Maiuri M, Denis HL, Masnata M, Fazal SV, Chouinard S, Rosa-Neto P, Barker RA, Blennow K, Zetterberg H, Labib R, Cicchetti F

Journal of neurology2025Senior author

DOI: 10.1007/s00415-025-12966-9 PMID: 40047995

Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson's disease.

Kerdiles O, Oye Mintsa Mi-Mba MF, Coulombe K, Tremblay C, Émond V, Saint-Pierre M, Rouxel C, Berthiaume L, Julien P, Cicchetti F, Calon F

Neural regeneration research2025

DOI: 10.4103/nrr.nrr-d-23-00595 PMID: 38819068

Restoring brain barriers: an innovative approach for treating neurological disorders.

Lemarchant S, Engelhardt B, Cicchetti F, Bix GJ, Janus A, Godfrin Y, Blasco H, Campbell M, de Rus Jacquet A

Fluids and barriers of the CNS2025

DOI: 10.1186/s12987-025-00688-z PMID: 40640916

Parkinson's Disease-vulnerable and -resilient dopamine neurons display opposite responses to excitatory input.

Hadjas LC, Kollman GJ, Linderhof L, Xia M, Mansur S, Saint-Pierre M, Lim BK, Lee EB, Cicchetti F, Awatramani R, Hollon NG, Hnasko TS

bioRxiv : the preprint server for biology2025

DOI: 10.1101/2025.06.03.657460 PMID: 40501779

Treatment with Tau fibrils impact Huntington's disease-related phenotypes in cell and mouse models.

Salem S, Alpaugh M, Saint-Pierre M, Alves-Martins-Borba FN, Cerquera-Cleves C, Lemieux M, Ngonza-Nito SB, De Koninck P, Melki R, Cicchetti F

Neurobiology of disease2024Senior author

DOI: 10.1016/j.nbd.2024.106696 PMID: 39389154

Evidence of mutant huntingtin and tau-related pathology within neuronal grafts in Huntington's disease cases.

Salem S, Kilgore MD, Anwer M, Maxan A, Child D, Bird TD, Keene CD, Cicchetti F, Latimer C

Neurobiology of disease2024

DOI: 10.1016/j.nbd.2024.106542 PMID: 38810948

Something wrong or missing on this profile? Suggest a correction

Francesca Cicchetti

Research

Latest papers

Latest funding

WDR44 drives de novo &#x3b1;-synuclein aggregation at the lysosomal membrane and promotes neuronal dysfunction in Parkinson's Disease.

Mutant huntingtin in the extracellular matrix: A new perspective on Huntington's disease pathology.

The impact of tau deletion on Huntington's disease: An in vivo perspective.

Erythrocyte-derived extracellular vesicles transcytose across the blood-brain barrier to induce Parkinson's disease-like neurodegeneration.

Tau levels in platelets isolated from Huntington's disease patients serve as a biomarker of disease severity.

Additive neurorestorative effects of exercise and docosahexaenoic acid intake in a mouse model of Parkinson's disease.

Restoring brain barriers: an innovative approach for treating neurological disorders.

Parkinson's Disease-vulnerable and -resilient dopamine neurons display opposite responses to excitatory input.

Treatment with Tau fibrils impact Huntington's disease-related phenotypes in cell and mouse models.

Evidence of mutant huntingtin and tau-related pathology within neuronal grafts in Huntington's disease cases.

Frequent collaborators

Abid Oueslati

Steve Lacroix

Emmanuel Planel

Martin Parent

Eric Boilard

Jasna Kriz

Arnaud Droit

Thomas Durcan

Oury Monchi

Paul Isenring

Ray Truant

Louis-Eric Trudeau

Pedro Rosa-Neto

Shirley Fecteau

Marie-Ève Tremblay

Marie-Ève Tremblay

Janelle Drouin-Ouellet

Jason Karamchandani

Madeleine Sharp

Jean-Francois Poulin

Jean-Baptiste Poline

Davide Martino

Jason Karamchandani

Angela Genge

Martin Lévesque

Armen Saghatelyan

Alain Dagher

Michel Panisset

Denis Soulet

Frédéric Calon

Reza Sharif-Naeini

WDR44 drives de novo α-synuclein aggregation at the lysosomal membrane and promotes neuronal dysfunction in Parkinson's Disease.